2026, Clinical Trials, Scientific Sessions, Session Coverage
  • Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1

    Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1

    Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes.


  • Primary results for SOLSTICE and VISTA to be shared for the first time

    Primary results for SOLSTICE and VISTA to be shared for the first time

    Vanita R. Aroda, MD, and Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, will review the latest data for a novel oral glucagon-like peptide-1 receptor agonist in people living with with type 2 diabetes or overweight or obesity.


  • Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management

    Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management

    John B. Buse, MD, PhD, and other researchers will share study results and a broad understanding of amylin, from the hormone’s biology to potential translation to clinical care via phase 3 trials.